- CA$102.79m
- CA$108.07m
- CA$1.98m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 74.29 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -173.29% | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.09 | 0.07 | 3.89 | 0.96 | 1.98 | 2 | 2 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.
Directors
- Richard Muruve PRE
- Daniel Muruve CSO
- Andrew Bishop DRC
- Claude Allary IND
- Adrian Haigh IND (61)
- Richard Rossman IND
- Last Annual
- September 30th, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- November 13th, 2003
- Public Since
- October 9th, 1996
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
TSX Venture Exchange- Shares in Issue
- 64,650,633
- Address
- 545 King St W., TORONTO, M5X 1A1
- Web
- https://archbiopartners.com/
- Phone
- +1 6474287031
- Contact
- Richard Muruve
- Auditors
- Baker Tilly HMA LLP
Upcoming Events for ARCH
Q1 2025 Arch Biopartners Inc Earnings Release
Similar to ARCH
Aequus Pharmaceuticals
TSX Venture Exchange
Avricore Health
TSX Venture Exchange
Biosyent
TSX Venture Exchange
Cytophage Technologies
TSX Venture Exchange
Decibel Cannabis
TSX Venture Exchange
FAQ
What is the Arch Biopartners share price?
As of Today at 19:46 UTC, shares in Arch Biopartners are trading at CA$1.59. This share price information is delayed by 15 minutes.
How has the Arch Biopartners share price performed this year?
Shares in Arch Biopartners last closed at CA$1.59 and the price had moved by +1.29% over the past 365 days. In terms of relative price strength the Arch Biopartners share price has underperformed the Toronto Stock Exchange 300 Composite Index by -11.37% over the past year.
What are the analyst and broker recommendations for Arch Biopartners?
The overall consensus recommendation for Arch Biopartners is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Arch Biopartners dividend yield?
Arch Biopartners does not currently pay a dividend.
Does Arch Biopartners pay a dividend?
Arch Biopartners does not currently pay a dividend.
When does Arch Biopartners next pay dividends?
Arch Biopartners does not currently pay a dividend.
How do I buy Arch Biopartners shares?
To buy shares in Arch Biopartners you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Arch Biopartners?
As of the previous close price of CA$1.59, shares in Arch Biopartners had a market capitalisation of CA$102.79m.
Where are Arch Biopartners shares listed?
Here are the trading details for Arch Biopartners:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: ARCH
What kind of share is Arch Biopartners?
Based on an overall assessment of its quality, value and momentum Arch Biopartners is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Arch Biopartners share price forecast for 2024?
The analyst consensus target price for shares in Arch Biopartners is CA$3.50. That is 120.13% above the last closing price of CA$1.59.
Analysts covering Arch Biopartners currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.07 for the next financial year.
Find out moreWhat is the trend in the Arch Biopartners share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arch Biopartners. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -33.88%.
As of the last closing price of CA$1.59, shares in Arch Biopartners were trading -4.97% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Arch Biopartners PE Ratio?
The Arch Biopartners PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$1.59.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Arch Biopartners?
Arch Biopartners' management team is headed by:
- Richard Muruve - PRE
- Daniel Muruve - CSO
- Andrew Bishop - DRC
- Claude Allary - IND
- Adrian Haigh - IND
- Richard Rossman - IND